|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1600 - 0.1850|
|52 Week Range||0.1150 - 3.2700|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Elixinol, a global hemp derived CBD brand, announced it has named Tom Siciliano as the organization's new CEO Americas effective immediately. Siciliano is charged with leading Elixinol's refined strategy on hemp derived CBD in the Americas region.
Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, is pleased to announce that it has acquired the intellectual property rights over microencapsulated technology developed by Bionova. This transaction will allow Elixinol to utilize the microencapsulated technology globally.
Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, recently announced that its parent company Elixinol Global (EXL) has raised A$50 million through the issue of approximately 12.8 million shares at A$3.90 per share to institutional investors. Proceeds acquired will be used to further expand operations in Colorado, Elixinol’s U.S. headquarters. The rapid growth displayed here is set to amplify the company’s presence in the U.S. by increasing production facilities in Colorado by an additional ~23,000 square feet to more than double the company’s current production capacity.
The Food and Drug Administration held its first-ever hearing on CBD Friday, and market leaders gave testimony on the state of the industry and what they hope it will look like going forward. One participant, ...
NEW YORK , June 4, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the launch of the OTCQX® Cannabis Index ...
DENVER, June 03, 2019 -- Elixinol issued the following statement regarding the public FDA hearing in Washington, D.C. on Friday, May 31. “We support the FDA’s intentions, we.